| |
France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment
|
| |
| |
French Govt Announces Universal HCV Drug Access Plan
http://www.natap.org/2016/HCV/060216_01.htm
3/31/2017
The French Ministry of Social Affairs and Health announced today that the ministry has negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines.
According to the ministry's press release (in French), the price decrease for the drugs Harvoni and Sovaldi is described as "very substantial." New prices are expected to come into effect on 1 April. For Sovaldi, it will drop from $41,000 euros to less than $28,700 euros for the treatment of hepatitis C, it said.
The new prices will allow continued universal access to hepatitis C for patients in France, the release said. Hepatitis C treatments are integrally supported by the French social security system, which will benefit from those new prices, it added.
http://solidarites-sante.gouv.fr/archives/archives-presse/archives-communiques-de-presse/article/acces-universel-aux-traitements-contre-l-hepatite-c-marisol-touraine-obtient
Universal Access to Hepatitis C Treatments: Marisol Touraine Achieves Significant Price Decline
translation from French
Marisol Touraine, Minister of Social Affairs and Health, pledged on May 25 to guarantee universal access to hepatitis C treatment. This commitment is accompanied by a strong desire to lower the prices of hepatitis C. these drugs, which are particularly high today: the minister asked the Economic Committee for Health Products (CEPS) to hold an extremely strong negotiation with the laboratories in this respect. The agreement signed today with the MSD laboratory comes to concretize these efforts, by attributing to Zepatier®, new treatment against hepatitis C, a price significantly lower than all the other treatments available on the market.
Zepatier® will be sold at a price of $28,732 (before confidential discounts) for a treatment of 12 weeks. This price is nearly 38% lower than the other hepatitis C drugs currently available on the market.
Marisol Touraine is delighted with this agreement, which proves the government's total determination to guarantee, through a voluntarist policy of price reduction, access for all hepatitis C patients to new treatments for this disease. The minister will specify in the coming days the framework guaranteeing universal access to these drugs, on the basis of the opinion of the college of the High Authority of Health (HAS) and recommendations on the organization of the medical care and patient monitoring.
http://solidarites-sante.gouv.fr/archives/archives-presse/archives-communiques-de-presse/article/acces-universel-aux-traitements-innovants-contre-l-hepatite-c-apres-avoir
Universal access to innovative treatments for hepatitis C: After allowing all patients access to treatment, Marisol Touraine gets a significant price cut
After announcing universal access to innovative treatments for hepatitis C on May 25, 2016, Marisol Touraine, Minister of Social Affairs and Health, obtained a significant price reduction of innovative treatments against hepatitis C. will be published very soon and will allow these new rates to come into effect as of April 1, 2017. This is another step to ensure the sustainability of our health system and the access of all patients to innovative treatments.
At the request of the Minister, the Economic Committee for Health Products (CEPS) held a firm negotiation with the laboratories. After a first agreement concluded on December 8, 2016 with the MSD laboratory, the negotiations to lower the prices of HCV treatments have just ended with the agreement reached with the Gilead laboratory for its Harvoni® and Sovaldi® products.
From now on, the price of the treatments will be lower than 28 700 $, against 41 000 $ for the Sovaldi® previously. Marisol TOURAINE now allows all patients with hepatitis C to benefit from innovative treatments at prices much lower than before. All these treatments are 100% covered by the Health Insurance. The accounts are therefore all the better.
"These agreements demonstrate the effectiveness of the proactive policy I have been pursuing for several months to bring down drug prices. This is good news for patients. This is good news for social security accounts, "said Marisol Touraine
| |
| |
| |
|
|
|
